J Cell Physiol 2006, 207:520–529 PubMedCrossRef

8 Caloge

J Cell Physiol 2006, 207:520–529.PubMedCrossRef

8. Calogero A, Pavoni E, Gramaglia T, D’Amati G, Ragona G, Brancaccio A, et al.: Altered exression of a-dystroglycan subunit in human gliomas. Cancer Biol Ther 2006, buy Pevonedistat 5:441–448.PubMedCrossRef 9. Sgambato A, Camerini A, Montanari M, Camerini A, Brancaccio A, Spada D, et al.: Increased expression of dystroglycan inhibits the growth and tumorigenicity of human mammary epithelial cells. Cancer Biol Ther 2004, 3:849–860. 10. Sgambato A, De Paola B, Migaldi M, Di Salvatore M, Rettino A, Rossi G, et al.: Dystroglycan expression is reduced during prostate tumorigenesis and is regulated by androgens in prostate cancer cells. J Cell Physiol 2007, 213:528–539.PubMedCrossRef 11. Compton C, Greene F: The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin 2004, 54:295–308.PubMedCrossRef

12. Sgambato A, Migaldi M, Montanari M, Camerini A, Brancaccio A, Rossi G, et al.: Dystroglycan expression is frequently reduced in human breast and colon cancers and is associated with tumor progression. Am J Pathol 2003, 162:849–860.PubMedCrossRef 13. Zannoni G, Faraglia B, Tarquini E, Camerini A, Vrijens K, Migaldi M, et al.: Expression of the CDK inhibitor p27kip1 and oxidative DNA damage in non-neoplastic and neoplastic vulvar epithelial lesions. Mod Pathol 2006, 19:504–513.PubMedCrossRef 14. Sgambato A, Tarquini E, Resci F, De Paola B, Faraglia B, Camerini A, et al.: Aberrant expression of alpha-dystroglycan in cervical and vulvar cancer. Gynecol Oncol 2006, 103:397–404.PubMedCrossRef Selleckchem PD0332991 15. Jiang X, Rieder S, Giese N, Friess H, Michalski C, Kleeff J: Reduced alpha-dystroglycan expression correlates with shortened patient survival in pancreatic cancer. J Surg Res 2011, 171:120–126.PubMedCrossRef 16. Shen JG, Xu CY, Li X, Dong M, Jiang ZN, Wang J, et al.: Dystroglycan is associated with Methocarbamol tumor progression and patient survival in gastric cancer. Pathol Oncol Res 2012, 18:79–84.PubMedCrossRef 17. Bao X, Fukuda M: A tumor suppressor function of laminin-binding alpha-dystroglycan. Methods Enzymol 2010, 479:387–396.PubMedCrossRef 18. Brennan P, Jing J, Ethunandan M, Gorecki D: Dystroglycan complex in cancer.

Eur J Surg Oncol 2004, 30:589–592.PubMedCrossRef 19. Henry MD, Cohen MB, Campbell KP: Reduced expression of dystroglycan in breast and prostate cancer. Hum Pathol 2001, 32:791–795.PubMedCrossRef 20. Cross S, Lippitt J, Mitchell A, Hollingsbury F, Balasubramanian S, Reed M, et al.: Expression of Liproxstatin 1 beta-dystroglycan is reduced or absent in many human carcinomas. Histopathology 2008, 53:561–566.PubMedCrossRef 21. Losasso C, Di Tommaso F, Sgambato A, Ardito R, Cittadini A, Giardina B, et al.: Anomalous dystroglycan in carcinoma cell lines. FEBS Lett 2000, 484:194–198.PubMedCrossRef 22. Herzog C, Has C, Franzke C-W, Echtermeyer F, Schlotzer-Schrehardt U, Kroger S, et al.: Dystroglycan in skin and cutaneous cells: ß-subunit is shed from the cell surface.

Related posts:

1. Mol Cell Biochem 2006, 286: 67–76 PubMedCrossRef 13 Fong WG, Lis
2. The significance of this observation is unknown since no data are
3. J Bacteriol 2006,188(21):7396–7404 PubMedCrossRef 30 Hinderhofer
4. J Bacteriol
   
   2006,188(6):2290–2293 PubMedCrossRef 17 Mars
5. Stem Cells 2008,26(6):1414–1424 PubMedCrossRef 12 Chung LW, Base